Carmell Therapeutics Corporation (CTCX)
USD 0.2
(1.39%)
USD 0.2
(1.39%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | - | - | - |
| Cost of Revenue | 124.78 Thousand | 242.55 Thousand | - |
| Gross Profit | -124.78 Thousand | -242.55 Thousand | - |
| Operating Expenses | 5.09 Million | 5.5 Million | 1.94 Million |
| Selling, General and Administrative Expenses | 2.59 Million | 3.21 Million | 863.33 Thousand |
| Research and Development Expenses | 2.49 Million | 2.19 Million | 982.83 Thousand |
| Other Expenses | - | 10.92 Thousand | 37.37 Thousand |
| Cost and Expenses | 5.21 Million | 5.5 Million | 1.94 Million |
| Operating Income | -5.21 Million | -5.5 Million | -1.94 Million |
| Interest Expense | 889.31 Thousand | 3.74 Million | 2.49 Million |
| Income Tax Expense | -760.16 Thousand | 391.19 Thousand | 2.53 Million |
| Earnings before Tax | -16.2 Million | -9.05 Million | -6.47 Million |
| Net Income | -15.44 Million | -9.05 Million | -6.47 Million |
| Earnings Per Share Basic | -1.46 | -0.46 | -0.33 |
| Earnings Per Share Diluted | -1.46 | -0.46 | -0.33 |
| Weighted Average Shares Outstanding | 11.02 Million | 19.76 Million | 19.76 Million |
| Weighted Average Shares Outstanding (Diluted) | 11.02 Million | 19.76 Million | 19.76 Million |
| Gross Margin | - | - | - |
| EBIT Margin | - | - | - |
| Profit Margin | - | - | - |
| EBITDA | -15.19 Million | -5.25 Million | -1.66 Million |
| Earnings Before Tax Margin | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 12.32 Thousand | - | - | -3.72 Million | 3.72 Million | - |
| Cost of Revenue | 58.56 Thousand | 57.57 Thousand | 124.78 Thousand | - | 1.54 Million | - |
| Gross Profit | -46.24 Thousand | -57.57 Thousand | -124.78 Thousand | -3.72 Million | 2.18 Million | - |
| Operating Expenses | 1.14 Million | 1.32 Million | 5.09 Million | -4.14 Million | 6.59 Million | 1.16 Million |
| Selling, General and Administrative Expenses | 1.04 Million | 893.35 Thousand | - | -3.01 Million | 4.49 Million | 1.16 Million |
| Research and Development Expenses | 104.06 Thousand | 429.42 Thousand | - | -738.67 Thousand | 1.67 Million | 823.65 Thousand |
| Other Expenses | 19.77 Thousand | 9054.00 | - | 31 Thousand | 3683.00 | -461.00 |
| Cost and Expenses | 1.2 Million | 1.38 Million | 5.21 Million | -5.68 Million | 8.13 Million | 1.16 Million |
| Operating Income | -1.19 Million | -1.38 Million | -5.21 Million | 1.95 Million | -5.13 Million | -1.16 Million |
| Interest Expense | 9345.00 | 25.03 Thousand | 889.31 Thousand | -47.69 Thousand | 397.68 Thousand | 276.03 Thousand |
| Income Tax Expense | - | 1.25 Million | -760.16 Thousand | -776.85 Thousand | 401.36 Thousand | 388.62 Thousand |
| Earnings before Tax | -3.3 Million | -3.55 Million | -16.2 Million | 2.39 Million | -11.46 Million | 706.13 Thousand |
| Net Income | -3.3 Million | -4.8 Million | -15.44 Million | 3.15 Million | -11.46 Million | 317.51 Thousand |
| Earnings Per Share Basic | -0.16 | -0.21 | - | 0.29 | -0.62 | 0.02 |
| Earnings Per Share Diluted | -0.16 | -0.21 | - | 0.29 | -0.62 | 0.02 |
| Weighted Average Shares Outstanding | 20.73 Million | 22.91 Million | 11.02 Million | 11.02 Million | 18.62 Million | 19.76 Million |
| Weighted Average Shares Outstanding (Diluted) | 20.73 Million | 22.91 Million | 11.02 Million | 11.02 Million | 18.62 Million | 19.76 Million |
| Gross Margin | -3.75 | - | - | 1.00 | 0.59 | - |
| EBIT Margin | -91.98 | - | - | -0.44 | -1.07 | - |
| Profit Margin | -268.23 | - | - | -0.85 | -3.07 | - |
| EBITDA | -1.13 Million | -1.32 Million | - | 1.63 Million | -3.97 Million | -3.02 Million |
| Earnings Before Tax Margin | -96.71 | - | - | -0.52 | -1.38 | - |
BGAVF
NUGN
SCP
CLPHF
SIEGY
BBXIA